MedTrace Logo

Medication Adherence Program

NCT05183763 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2026-05-20

No results posted yet for this study

Summary

Randomized controlled trial testing the efficacy of the Supporting Tailored Adaptive change and Reinforcement for Medication Adherence Program (STAR-MAP), a health coaching approach that aims to improve antihypertensive medication adherence, blood pressure control, and quality of life. Participants (n=402) \>=40 years old with a diagnosis of hypertension, uncontrolled blood pressure, and low antihypertensive medication adherence will be recruited through a statewide health insurer, Blue Cross Blue Shield of Louisiana, and randomized to receive either interactive health coaching sessions with medication reminder tools (intervention) or medication reminder tools only (control) over one year. Data will be collected from participants at baseline, 6 months, 12 months, and 24 months using questionnaires, physical measurement (height, weight, blood pressure), a computer-based single-category implicit association test, and laboratory analysis of antihypertensive medication urinary metabolites.

Conditions

  • Hypertension
  • Medication Adherence
  • Behavior and Behavior Mechanisms

Interventions

BEHAVIORAL

STAR-MAP health coaching

Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior

BEHAVIORAL

Medication reminder tools

Medication-taking reminder app and pillbox

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • Minds at Work

    collaborator UNKNOWN

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Tulane University

    lead OTHER

Principal Investigators

  • Marie A Krousel-Wood, MD, MSPH · Tulane University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05183763 on ClinicalTrials.gov